Key Summary Points {#FPar1}
==================

**Why carry out this study?**Type 2 diabetes (T2D) is associated with a significant clinical and economic burden in the UKIn order to manage and allocate healthcare budgets, the UK National Health Service (NHS) relies on value-based decisions to ensure that funded interventions represent good value for moneyThe aim of this analysis was to evaluate, from a UK perspective, the relative cost of achieving treatment goals in people with T2D treated with once-weekly semaglutide 1 mg versus the glucagon-like peptide 1 receptor agonists exenatide extended-release (ER) 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg**What was learned from the study?**The present study showed that once-weekly semaglutide 1 mg offers superior cost of control versus exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg in terms of achieving clinically relevant, single and composite endpointsOnce-weekly semaglutide 1 mg would therefore represent good value for money in the UK

Introduction {#Sec1}
============

Diabetes is associated with a significant clinical and economic burden in the UK. Approximately 6% of the UK population are affected by diabetes, 90% of whom have type 2 diabetes (T2D) \[[@CR1], [@CR2]\]. Diabetes is associated with significant microvascular and macrovascular complications, and every week in the UK around 500 people with diabetes die prematurely \[[@CR2], [@CR3]\]. The prevention and treatment of diabetes, together with the burden of managing related complications, are associated with a high financial burden; in 2017, diabetes-related healthcare expenditure exceeded GBP 10 billion \[[@CR1]\]. Diabetes, its comorbidities and the requirement for monitoring and management also result in a considerable humanistic burden and reduced quality of life \[[@CR4]\]; diabetes is the leading cause of blindness in people of working age in the UK, and each week over 100 amputations are carried out on people with diabetes \[[@CR2], [@CR3], [@CR5]--[@CR7]\].

Reductions in glycated haemoglobin (HbA1c), an indicator of glycaemic control, are associated with a lowered risk of long-term diabetes complications \[[@CR8]--[@CR10]\]. However, treatments that can lower blood glucose levels and reduce HbA1c are associated with an inherent risk of hypoglycaemia. Severe hypoglycaemia can increase the risk of cardiovascular complications and all-cause mortality \[[@CR11]\], as well as negatively affect patients' well-being \[[@CR12], [@CR13]\]. For this reason, treatments with a low risk of hypoglycaemia may be of value to people with diabetes. In the UK, the National Institute for Health and Care Excellence (NICE) recommends a target HbA1c of ≤ 6.5%, ≤ 7.0% or less stringent thresholds for people with T2D, depending on the individual patient requirements and their risk of hypoglycaemia \[[@CR14]\]. However, in a 2016--2017 audit of England and Wales, only 67% of people with T2D or other types of diabetes (excluding type 1 diabetes) were found to achieve target HbA1c levels of ≤ 7.5% \[[@CR15]\]. Reduction in body weight is also associated with a lower long-term risk of complications; consequently, NICE recommends a weight loss target of 5--10% for patients above a healthy weight \[[@CR14], [@CR16], [@CR17]\]. Therefore, a triple composite target of HbA1c \< 7.0% without weight gain and without hypoglycaemia can be considered a key metric when assessing quality of care. The target of HbA1c \< 7.0% was chosen on the basis of the American Diabetes Association's (ADA's) clinical practice guidelines because these are well recognized globally \[[@CR18]\]. Management strategies to achieve this composite endpoint have the potential to both reduce costs and improve quality of life \[[@CR8]--[@CR10], [@CR14], [@CR16]\].

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of highly effective diabetes therapies that are associated with improved glycaemic control, reductions in body weight and a low hypoglycaemia risk \[[@CR19]\]. Once-weekly semaglutide 1 mg (Ozempic^®^; Novo Nordisk A/S) is a novel GLP-1 RA that, throughout the SUSTAIN clinical trial programme, has demonstrated greater reductions in HbA1c and body weight than the other GLP-1 agonists exenatide extended-release (ER) 2 mg (Byetta^®^; AstraZeneca) \[[@CR20]\], dulaglutide 1.5 mg (Trulicity^®^; Eli Lilly) \[[@CR21]\] and liraglutide 1.2 mg (Victoza^®^; Novo Nordisk A/S) \[[@CR22]\]. Once-weekly semaglutide 1 mg was granted marketing authorisation in 2018 for use in adults with insufficiently controlled T2D as an adjunct to diet and exercise by the European Medicines Agency \[[@CR23]\]. According to current guidance from the NICE, GLP-1 RAs are recommended for patients with T2D and obesity if triple therapy with metformin and two other oral drugs is not effective, not tolerated or contraindicated \[[@CR14]\].

The UK National Health Service (NHS) relies on value-based decisions to manage and allocate healthcare budgets and ensure that funded interventions represent good value for money \[[@CR24], [@CR25]\]. In a recent long-term analysis, once-weekly semaglutide 1 mg was found to be cost-effective for the treatment of T2D in the UK, compared with dulaglutide 1.5 mg \[[@CR26]\]. Short-term economic analyses, such as cost of control analyses, complement longer-term analyses and are useful to assess and easily compare the cost-effectiveness of multiple new treatments. Cost of control analyses are easy to conduct and interpret, and can be readily repeated for different comparators and from different perspectives. In recent cost of control analyses, once-weekly semaglutide 1 mg showed favourable cost-effectiveness compared with exenatide ER 2 mg and dulaglutide 1.5 mg in the USA and in Canada \[[@CR27], [@CR28]\], and compared with dulaglutide 1.5 mg, exenatide ER 2 mg, sitagliptin 100 mg and insulin glargine U100 in the UK \[[@CR29]\].

The aim of this analysis was to evaluate, from a UK perspective, the relative cost of control of achieving treatment targets in people with T2D treated with once-weekly semaglutide 1 mg versus exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg.

Methods {#Sec2}
=======

Clinical Data {#Sec3}
-------------

Published clinical data for the analysis were taken from the SUSTAIN 3 \[[@CR20]\], SUSTAIN 7 \[[@CR21]\] and SUSTAIN 10 \[[@CR22]\] trials, which compared once-weekly semaglutide 1 mg with exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg, respectively. In addition to GLP-1 RAs, patients received 1--2 oral antidiabetic drugs in SUSTAIN 3, metformin in SUSTAIN 7 and 1--3 oral antidiabetic drugs in SUSTAIN 10. These comparators were chosen in order to compare once-weekly semaglutide 1 mg with GLP-1 RAs that are widely available in the UK.

The analysis was based on the proportion of patients from the SUSTAIN trials achieving the following target endpoints with each intervention:HbA1c ≤ 6.5%, \< 7.0% and \< 7.5%Weight loss ≥ 5% and ≥ 10%Composite endpoints of HbA1c \< 7.0% without weight gain and without hypoglycaemia, and a reduction in HbA1c of ≥ 1% with weight loss of ≥ 5%

The baseline characteristics of patients and the proportion of patients who achieved target endpoints included in the analysis are shown in Table [1](#Tab1){ref-type="table"}. HbA1c \< 7.5% was calculated in a post hoc analysis of the SUSTAIN trials, and the composite endpoint of a reduction in HbA1c of ≥ 1% with weight loss of ≥ 5% for once-weekly semaglutide 1 mg versus exenatide ER 2 mg was calculated in a post hoc analysis of SUSTAIN 3 \[[@CR30]\]. The statistical significance of differences between treatments was assessed using a logistic regression model.Table 1Baseline characteristics of patients and endpoints in SUSTAIN 3, SUSTAIN 7 and SUSTAIN 10SUSTAIN 3SUSTAIN 7SUSTAIN 10Once-weekly semaglutide 1 mgExenatide ER 2 mgOnce-weekly semaglutide 1 mgDulaglutide 1.5 mgOnce-weekly semaglutide 1 mgLiraglutide 1.2 mgIntent-to-treat population (*n*)404405300299290287Treatment period (weeks)564030Baseline characteristics Age (years)56.456.7555660.158.9 Duration of diabetes (years)9.09.47.37.69.68.9 Body mass index (kg/m^2^)34.033.633.633.133.733.7 Baseline HbA1c (%)8.48.38.28.28.28.3Antidiabetic medications at screening (%) Biguanides96.896.310010096.293.4 Sulfonylureas44.851.4----46.946.7 Sodium--glucose cotransporter 2 inhibitors--------25.224.0 Thiazolidinediones3.21.5-------- Dipeptidyl peptidase 4 inhibitors--------00.3\* Other blood glucose-lowering drugs (excluding insulin)0.2^†^0.5^†^----0.30 Long-acting insulins and analogues for injection00.2^†^--------HbA1c endpoints Change in HbA1c from baseline to end of trial (%)-- 1.5^‡^-- 0.9-- 1.8^§^-- 1.4-- 1.7^¶^-- 1.0 Proportion of patients achieving HbA1c ≤ 6.5% (%)4722674758.524.8 Proportion of patients achieving HbA1c \< 7.0% (%)6740796780.445.9 Proportion of patients achieving HbA1c \< 7.5% (%)78.258.088.078.392.567.6Weight loss endpoints Proportion of patients achieving weight loss ≥ 5% (%)5217633055.917.7 Proportion of patients achieving weight loss ≥ 10% (%)21427819.14.4Composite endpoints Proportion of patients achieving HbA1c \< 7.0% without weight gain and without hypoglycaemia (%)5628745875.636.8 Proportion of patients achieving a ≥ 1% reduction in HbA1c and ≥ 5% weight loss (%)4313592349.611.9Values presented are means, unless stated otherwise*ER* extended-release, *HbA1c* glycated haemoglobin\* Patients receiving dipeptidyl peptidase 4 inhibitors and repaglinide were randomized in error and discontinued treatment^†^Patients receiving other blood glucose-lowering drugs and long-acting insulins and analogues for injection were randomized in error and discontinued treatment^‡^*p* \< 0.0001 versus exenatide ER 2 mg^§^*p* \< 0.0001 versus dulaglutide 1.5 mg^¶^*p* \< 0.0001 versus liraglutide 1.2 mg

Cost Data, Resource Use, Time Horizon and Perspective of the Analysis {#Sec4}
---------------------------------------------------------------------

The analysis was conducted from the perspective of the NHS in 2019, with outcomes projected over a 1-year time horizon. For simplicity, only wholesale acquisition prices were used to calculate costs for each therapy at the recommended dose; UK prices were taken from the Monthly Index of Medical Specialities (MIMS; sourced 19 July 2019; Table [2](#Tab2){ref-type="table"}) \[[@CR31]\]. Costs related to self-monitoring of blood glucose were assumed to be the same for each treatment regimen; therefore, these costs were not included. Costs for needles for once-weekly semaglutide 1.2 mg, exenatide ER 2 mg and dulaglutide 1.5 mg are included in the pack price; therefore, any costs related to needles are already accounted for. Costs for needles for liraglutide 1.2 mg are not included in the pack price, but for simplicity these were not included as an additional cost. Adherence to all modelled regimens was assumed to be 100%.Table 2UK prices for once-weekly semaglutide, exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mgDrugPack contentsPack price (GBP) from MIMS \[[@CR31]\]Annual cost (GBP)Semaglutide 1 mg4 mg0.5 mg, 4-dose pre-filled pen, 1 = GBP 73.259561.0 mg, 4-dose pre-filled pen, 1 = GBP 73.25Exenatide ER 2 mg8 mg2.0 mg powder and solvent for sustained-release suspension for injection, pre-filled pen, 4 = GBP 73.36957Dulaglutide 1.5 mg6 mg1.5 mg/0.5 ml pre-filled pen, 4 = GBP 73.25956Liraglutide 1.2 mg36 mg3 ml pre-filled pens, 2 = GBP 78.48955*ER* extended-release, *MIMS* Monthly Index of Medical Specialities

Model and Relative Cost of Control Calculations {#Sec5}
-----------------------------------------------

A model was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) to assess the relative costs of a single patient achieving each pre-specified single or composite endpoint in the three trials. This model has been used previously to evaluate the relative cost of control of once-weekly semaglutide 0.5 mg and 1 mg from a US perspective \[[@CR27]\].

Relative efficacy and costs were calculated by dividing the proportions of patients achieving each target and the medication acquisition costs for each comparator by the corresponding values for once-weekly semaglutide 1 mg from the relevant SUSTAIN trial. Efficacy outcomes from SUSTAIN 3, SUSTAIN 7 and SUSTAIN 10 were reported over 56 weeks, 40 weeks and 30 weeks of follow-up, respectively; however, a constant ratio of costs between the treatment arms over time was assumed to avoid disparities arising from these different trial durations.

The model results were presented in terms of relative cost of control outcomes only (i.e. cost relative to once-weekly semaglutide 1 mg and efficacy relative to once-weekly semaglutide 1 mg) using the same method as the cost of control analysis of once-weekly semaglutide 0.5 mg and 1 mg from a US perspective \[[@CR27]\]. Results were plotted on a cost--efficacy plane where the relative efficacy was plotted on the abscissa and the relative cost was plotted on the ordinate. Once-weekly semaglutide 1 mg was used as the reference and formed the identity line or line of equality (i.e. *x* = *y*). Comparators that fall above the line have a worse efficacy-to-cost ratio (incurring higher costs for the same efficacy or lower efficacy for the same cost), and those that fall below the line have a better efficacy-to-cost ratio (incurring lower costs for the same efficacy or higher efficacy for the same cost). The relationship between cost and efficacy was assumed to be linear.

Compliance with Ethics Guidelines {#Sec6}
---------------------------------

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec7}
=======

Annual Costs {#Sec8}
------------

The annual cost per patient was similar for once-weekly semaglutide, exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg (GBP 956, 957, 956 and 955, respectively).

HbA1c {#Sec9}
-----

Compared with once-weekly semaglutide 1 mg, exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg were 40.3%, 15.2% and 42.9% less efficacious in helping patients to achieve HbA1c \< 7.0%, respectively (Fig. [1](#Fig1){ref-type="fig"}a). A similar pattern was observed for target HbA1c \< 7.5% (25.8%, 11.0% and 26.9%, respectively) (Fig. [1](#Fig1){ref-type="fig"}b). Because the cost of treatment was similar, the efficacy-to-cost ratios of bringing patients to HbA1c targets of \< 7.0% and \< 7.5% were better with once-weekly semaglutide 1 mg than with exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg. When a target of HbA1c ≤ 6.5% was evaluated, a similar trend was seen (Fig. S1 in the supplementary material).Fig. 1Relative cost-to-efficacy ratio of bringing patients to a HbA1c target of **a** \< 7.0% and **b** \< 7.5%. ER extended-release

Weight Loss {#Sec10}
-----------

Once-weekly semaglutide 1 mg was also strongly differentiated from the comparators in helping patients to achieve weight loss. Compared with once-weekly semaglutide 1 mg, exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg were 67.3%, 52.4% and 68.3% less efficacious, respectively, in helping patients to achieve a weight loss of ≥ 5% (Fig. [2](#Fig2){ref-type="fig"}). Therefore, the efficacy-to-cost ratio of helping patients to achieve a weight loss of ≥ 5% was better with once-weekly semaglutide 1 mg than with exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg. A similar trend was seen when evaluating a weight loss target of ≥ 10% (Fig. S2 in the supplementary material).Fig. 2Relative cost-to-efficacy ratio of reducing patients' weight by 5% or more. ER extended-release

Composite Endpoint of HbA1c, Weight Loss and Hypoglycaemia {#Sec11}
----------------------------------------------------------

The trends observed for single endpoints were reflected in the results for composite endpoints, with once-weekly semaglutide 1 mg showing similar or greater differentiation versus comparators. Exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg were 50.0%, 21.6% and 51.3% less efficacious than once-weekly semaglutide 1 mg, respectively, in helping patients to achieve the composite endpoint of HbA1c \< 7.0% without weight gain or hypoglycaemia (Fig. [3](#Fig3){ref-type="fig"}a).Fig. 3Relative cost-to-efficacy ratio of **a** bringing patients to a HbA1c target of \< 7.0% without weight gain or hypoglycaemia or **b** reducing HbA1c by ≥ 1.0% and reducing weight by ≥ 5%. ER extended-release

Similarly, exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg were less efficacious than once-weekly semaglutide 1 mg (69.8%, 61.0% and 76.0%, respectively) in helping patients to achieve the composite endpoint of a reduction in HbA1c of ≥ 1.0% with a reduction in weight of ≥ 5% (Fig. [3](#Fig3){ref-type="fig"}b).

The efficacy-to-cost ratio of helping patients to achieve both of these composite endpoints was better with once-weekly semaglutide 1 mg than with exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg.

Discussion {#Sec12}
==========

The present study used data from SUSTAIN 3, SUSTAIN 7 and SUSTAIN 10 to assess the relative cost of control, defined as achieving various clinically relevant targets encompassing glycaemic control, weight gain and hypoglycaemia, for therapies used to treat people with T2D. From an NHS perspective, once-weekly semaglutide 1 mg offers a better cost-to-efficacy ratio than exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg for patients achieving these clinically relevant endpoints. Our results support those of previous cost of control analyses conducted in the USA and the UK, in which once-weekly semaglutide 1 mg was shown to provide better value for money than exenatide ER and dulaglutide in helping patients to reach a treatment target of HbA1c \< 7% without weight gain or hypoglycaemia \[[@CR27], [@CR29]\]. Our chosen targets for HbA1c and weight loss are clinically relevant, associated with reduced risk of diabetes-related complications and in line with current NICE guidance \[[@CR14]\] and our previous cost of control analyses \[[@CR27]\]. Furthermore, this is the first cost of control analysis comparing once-weekly semaglutide 1 mg with liraglutide 1.2 mg.

Strengths {#Sec13}
---------

Short-term analyses, such as ours, have several advantages over long-term analyses. These analyses can be easily updated if new clinical data become available or if wholesale acquisition costs change. Our analysis is based on a previously developed model and assumptions, permitting easy adaptation to a different setting \[[@CR27]\]. In addition, the analyses are easy to conduct and interpret, and provide a clear picture of relative cost-effectiveness for different treatments in terms of clinically relevant targets. Finally, no long-term projections of short-term data are required, avoiding the uncertainty associated with data extrapolation. Short-term cost-effectiveness analyses are intended to complement, rather than replace, long-term cost-effectiveness modelling, and can provide supportive evidence for the results of analyses that extrapolate over a longer time span. Our findings are similar to those of a previous long-term cost-effectiveness analysis of once-weekly semaglutide 1 mg versus dulaglutide 1.5 mg from a UK perspective, which found that once-weekly semaglutide 1 mg was associated with cost savings as well as improved outcomes \[[@CR26]\].

Limitations {#Sec14}
-----------

One limitation of our analysis is that it does not consider long-term complications or improvements in those patients who do not reach targets. Short-term reductions in HbA1c and body weight are associated with a reduced incidence of long-term diabetes-related complications \[[@CR8]--[@CR10], [@CR16]\]; therefore, the short-term efficacy benefits seen in the present analysis are likely to be associated with further benefits over patients' lifetimes. For this reason, the captured costs, time horizon and adopted budget perspective should all be considered when interpreting our cost of control analysis, and the results should be considered in the context of wider published cost-effectiveness evidence. In addition, adherence was assumed to be 100% for all treatments, which may not reflect clinical practice.

Another limitation of the current analysis is that only wholesale acquisition drug costs were used, with costs of blood glucose monitoring, interactions with healthcare professionals and adverse events (AEs) not being captured. Costs associated with blood glucose monitoring were assumed to be the same, regardless of treatment; however, wholesale acquisition costs include needles for once-weekly semaglutide 1 mg but not for liraglutide 1.2 mg. Consequently, the results of our analysis compared with liraglutide 1.2 mg are conservative because costs of needles would be greater for liraglutide 1.2 mg. AEs were not included in the present study because it focussed on endpoints pre-specified in the SUSTAIN trials, encompassing glycaemic control, weight gain and hypoglycaemia, and for parity with our previous cost of control analysis conducted in the USA \[[@CR27]\]. The only endpoint included that was not pre-specified and was generated post hoc was the target HbA1c of \< 7.5%; this endpoint was included because NICE recommends that patients intensify treatment when their HbA1c exceeds 7.5%, and this endpoint is therefore highly relevant for UK clinical practice \[[@CR14]\]. The inclusion of additional endpoints, such as AEs, in a modified cost of control analysis could be of interest in future studies; however, because the safety profiles of once-weekly semaglutide 1 mg, exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg were very similar in the SUSTAIN trial programme, we expect that this would not strongly affect the findings.

Finally, the periods of follow-up differed between studies: SUSTAIN 3 reported the proportions of patients reaching targets after 56 weeks, whereas SUSTAIN 7 and SUSTAIN 10 reported the same proportions over 40 weeks and 30 weeks, respectively. To mitigate the effect of this, cost and efficacy ratios, rather than absolute differences, were used. However, the differing follow-up periods should be considered in the interpretation and potential extrapolation of the outcomes.

Conclusions {#Sec15}
===========

The present analysis expanded on the results of the SUSTAIN 3, SUSTAIN 7 and SUSTAIN 10 clinical trials, which showed that once-weekly semaglutide 1 mg was more efficacious than exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg for helping patients to achieve clinically relevant endpoints comprising glycaemic control, weight loss and hypoglycaemia. Our analysis demonstrated that these endpoints could also be achieved more cost-effectively with once-weekly semaglutide 1 mg than with these comparators. Therefore, from the perspective of the NHS in the UK, once-weekly semaglutide 1 mg represents good value for money in the treatment of T2D, compared with exenatide ER 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg.
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